ClinicalOne study in 2205 people suggested that there may be an increase in all cause mortality in the fondaparinux group compared to the LMWH group, but it is uncertain whether this difference is clinically important because the event rate was low (LOW QUALITY).

One study in 2205 people showed it is very uncertain whether there is a clinically important difference in VTE related mortality between the fondaparinux group and the LMWH group (LOW QUALITY).

One study in 2205 people showed it is uncertain whether there is a clinically important difference in recurrent VTE rates between the fondaparinux group and the LMWH group (LOW QUALITY).

One study in 2205 people showed it is uncertain whether there is a clinically important difference in the number of people with major bleeding between the fondaparinux group and the LMWH group (LOW QUALITY).

One study in 2205 people suggested that there may be an increase in fatal bleeding in the fondaparinux group compared to the LMWH group, but it is very uncertain whether this difference is clinically important because the event rate was very low (VERY LOW QUALITY).
EconomicNo economic evidence was found for this question. A simple cost analysis showed a difference in drug costs between UFH, LMWH and fondaparinux. On average, fondaparinux is the most costly option.

From: 7, Pharmacological interventions

Cover of Venous Thromboembolic Diseases
Venous Thromboembolic Diseases: The Management of Venous Thromboembolic Diseases and the Role of Thrombophilia Testing [Internet].
NICE Clinical Guidelines, No. 144.
National Clinical Guideline Centre (UK).
Copyright © 2012, National Clinical Guideline Centre.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.